12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Safinamide: Phase III data

Newron said top-line data from the 24-week, double-blind, placebo-controlled, international Phase III MOTION trial in 679 patients with early idiopathic PD showed that once-daily 50 or 100 mg safinamide as an add-on to a stable dose of a single dopamine...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >